New antibody shows promise in slowing early myeloma
NCT ID NCT01222286
First seen May 20, 2026
Summary
This phase 2 trial tested an antibody drug called IPH2101 in 30 people with smoldering multiple myeloma, an early form of bone marrow cancer. The drug aims to boost the immune system to attack cancer cells. Researchers measured how well it controlled the disease and checked for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMOLDERING MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
Mount Sinai School of Medicine
New York, New York, 10029, United States
-
Ohio State University
Columbus, Ohio, 43210, United States
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IPH2101 (an antibody that helps immune cells attack cancer)
What this could lead to
If it works, this could point toward a treatment that delays or prevents smoldering multiple myeloma from becoming active cancer.
What could go wrong
This is a small, early-phase trial with only 30 participants, so results may not apply broadly. The drug may not shrink tumors or could cause side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.